arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PROTHENA CORP PUBLIC LTD CO

PRTA
$8.74 ▲ +0.17 (+1.92%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PROTHENA CORP PUBLIC LTD CO faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $470.5M
Dividend Yield
Revenue Growth -92.8%
Op. Margin None
ROIC -93.0%
FCF / Share $-3.04
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.68M
↓ -92.8%
Net Income Profit after all expenses
$-244.09M
↓ -99.6%
Operating Margin Operating profit as % of sales
-114.4%
↑ +45.3%
FCF / Share Free cash flow per share
$-3.04
↓ -8.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 59 quarters